Why the study?
Obese patients are highly sensitive to adriamycin-induced cardiotoxicity, but the underlying mechanism of superimposed toxicity remains to be elucidated.
Does SESN2 overexpression ameliorate adriamycin-induced cardiotoxicity in high-fat diet-induced obese mice?
Does SESN2 overexpression ameliorate adriamycin-induced cardiotoxicity in high-fat diet-induced obese mice?
SESN2 overexpression ameliorates anthracycline-related cardiotoxicity in obesity by upregulating NRF2 activity via the AKT/GSK-3β pathway.
Obesity-linked SESN2 reduction may heighten ADR cardiotoxicity risk; leaves open whether SESN2 targeting improves outcomes in obese patients.
Aims: Obese patients are highly sensitive to adriamycin (ADR)-induced cardiotoxicity. However, the potential mechanism of superimposed toxicity remains to be elucidated. Sestrin 2 (SESN2), a potential antioxidant, could attenuate stress-induced cardiomyopathy; therefore, this study aims to explore whether SESN2 enhances cardiac resistance to ADR-induced oxidative damage in high-fat diet (HFD)–induced obese mice. Results: The results revealed that obesity decreased SESN2 expression in ADR-exposed heart. And, HFD mice may predispose to ADR-induced cardiotoxicity, which was probably associated with inhibiting protein kinase B (AKT), glycogen synthase kinase-3 beta (GSK-3β) phosphorylation and subsequently blocking nuclear localization of nuclear factor erythroid-2 related factor 2 (NRF2), ultimately resulting in cardiac oxidative damage. However, these destructive cascades and cardiac oxidative damage effects induced by HFD/sodium palmitate combined with ADR were blocked by overexpression of SESN2. Moreover, the antioxidant effect of SESN2 could be largely abolished by sh- Nrf2 or wortmannin. And sulforaphane, an NRF2 agonist, could remarkably reverse cardiac pathological and functional abnormalities caused by ADR in obese mice. Innovation and Conclusion: This study demonstrated that SESN2 might be a promising therapeutic target for improving anthracycline-related cardiotoxicity in obesity by upregulating activity of NRF2 via AKT/GSK-3β/Src family tyrosine kinase signaling pathway. Antioxid. Redox Signal. 40, 598–615.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: